Stock Track | AKESO Soars 5.24% Intraday on Positive Phase II Pancreatic Cancer Trial Data

Stock Track

04/27

AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.

The sharp rise appears driven by continued positive investor sentiment following the release of encouraging clinical trial data. Recently at the AACR Annual Meeting, the company presented results from the COMPASSION-26 Phase II trial evaluating its PD-1/CTLA-4 bispecific antibody cadonilimab in combination with chemotherapy as a first-line treatment for advanced pancreatic ductal adenocarcinoma.

The data demonstrated robust anti-tumor activity with median overall survival reaching 23.4 months and median progression-free survival of 11.1 months in patients with locally advanced unresectable disease, representing meaningful improvement in a difficult-to-treat cancer indication.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1125463972"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125463972\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125463972?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 13:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125463972","market":"nz","top_or_hot":-1,"title":"Stock Track | AKESO Soars 5.24% Intraday on Positive Phase II Pancreatic Cancer Trial Data","media":"Stock Track","content":"<p>AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.</p><p>The sharp rise appears driven by continued positive investor sentiment following the release of encouraging clinical trial data. Recently at the AACR Annual Meeting, the company presented results from the COMPASSION-26 Phase II trial evaluating its PD-1/CTLA-4 bispecific antibody cadonilimab in combination with chemotherapy as a first-line treatment for advanced pancreatic ductal adenocarcinoma.</p><p>The data demonstrated robust anti-tumor activity with median overall survival reaching 23.4 months and median progression-free survival of 11.1 months in patients with locally advanced unresectable disease, representing meaningful improvement in a difficult-to-treat cancer indication.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AKESO Soars 5.24% Intraday on Positive Phase II Pancreatic Cancer Trial Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AKESO Soars 5.24% Intraday on Positive Phase II Pancreatic Cancer Trial Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-27 13:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.</p><p>The sharp rise appears driven by continued positive investor sentiment following the release of encouraging clinical trial data. Recently at the AACR Annual Meeting, the company presented results from the COMPASSION-26 Phase II trial evaluating its PD-1/CTLA-4 bispecific antibody cadonilimab in combination with chemotherapy as a first-line treatment for advanced pancreatic ductal adenocarcinoma.</p><p>The data demonstrated robust anti-tumor activity with median overall survival reaching 23.4 months and median progression-free survival of 11.1 months in patients with locally advanced unresectable disease, representing meaningful improvement in a difficult-to-treat cancer indication.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1125463972","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125463972","pubTimestamp":1777266211,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.The sharp rise appears driven by continued positive investor...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"个股追踪|康方生物盘中大涨5.24%胰腺癌II期试验数据积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.The sharp rise appears driven by continued positive investor sentiment following the release of encouraging clinical trial data. Recently at the AACR Annual Meeting, the company presented results from the COMPASSION-26 Phase II trial evaluating its PD-1/CTLA-4 bispecific antibody cadonilimab in combination with chemotherapy as a first-line treatment for advanced pancreatic ductal adenocarcinoma.The data demonstrated robust anti-tumor activity with median overall survival reaching 23.4 months and median progression-free survival of 11.1 months in patients with locally advanced unresectable disease, representing meaningful improvement in a difficult-to-treat cancer indication.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}